Dicaris 150 mg Tablets

Dicaris Combines a Single Adult Dose With Important Precautions

Dicaris is a 150 mg oral tablet containing levamisole, an anthelmintic, or worm medicine. The supplied product information identifies 150 mg as the established single-dose strength for adult anthelmintic treatment. That can make the regimen simpler than treatments requiring several doses, but it does not make Dicaris the right option for every worm infection or every patient. The parasite involved, previous blood disorders, pregnancy or breastfeeding, other medicines, and alcohol use all affect the decision.

There is also an important Canadian access consideration. Levamisole and its salts are on Health Canada's Prescription Drug List. In addition, a Canadian Drug Identification Number (DIN) and Canadian authorization holder for the exact Dicaris 150 mg product have not been identified from the available product information. Before ordering or using it in Canada, confirm the prescription, product identity, and authorization status with a prescriber, pharmacist, and Health Canada's Drug Product Database.

Product Identity and Established Role

Each Dicaris tablet in our catalogue contains levamisole 150 mg and is intended for oral use. It is a standard tablet, not a chewable, dispersible, modified-release, or liquid formulation. Those distinctions matter because a dosing instruction written for another strength or pharmaceutical form should not be applied automatically to this product.

Levamisole has an established role against certain susceptible worm infections. It should not be treated as a general remedy for every parasite, since different intestinal worms and other parasites respond to different medicines. Levamisole has also been investigated or used under specialist supervision for effects on immune responses in conditions such as persistent warts, lichen planus, and leprosy. These are not reasons to select Dicaris independently, and they may involve schedules that differ substantially from a single anthelmintic dose.

Manufacturer and market-specific labelling can also differ between packages. Our support team can help clarify the package details available through our catalogue, but the actual label and authorization status should be verified before supply or use.

Who Should Discuss Dicaris With a Prescriber?

The 150 mg tablet is the established adult or larger-body-weight strength. A prescriber will consider the diagnosis and several safety factors before deciding whether it is appropriate:

• Blood disorders: levamisole is contraindicated in people with relevant blood dyscrasias, including agranulocytosis or leukopenia. These terms refer to dangerously low levels of certain white blood cells.
• Pregnancy: human pregnancy data are inadequate. Established labelling advises against use, particularly during the first trimester, unless a clinician considers it clearly necessary.
• Breastfeeding: it is not established whether levamisole passes into human milk. Established guidance advises avoiding it while breastfeeding or following specific professional instructions about interrupting feeding around treatment.
• Allergy: known hypersensitivity to levamisole or another product ingredient is a contraindication. An unrelated or unspecified allergy history is not automatically a levamisole-specific restriction.
• Children: paediatric anthelmintic dosing is weight-based. The 150 mg tablet should not be substituted for an appropriate lower strength or calculated dose in a younger or lighter child.
• Diabetes: established oral levamisole labelling does not identify a diabetes-specific contraindication or routine dose adjustment, although the person's complete health history still matters.
• Alcohol use: levamisole can cause an unpleasant disulfiram-like reaction with alcohol, including flushing, nausea, vomiting, headache, or a rapid heartbeat.

This checklist supports a conversation with a qualified professional; it does not determine whether a particular person has a worm infection or should take levamisole.

How Does Levamisole Work in Practice?

Levamisole interferes with neuromuscular signalling in susceptible worms. This paralyzes the parasite, allowing it to be removed through normal intestinal movement. The medicine's activity depends on the parasite being susceptible, so a simple dosing pattern cannot compensate for an incorrect diagnosis or the wrong choice of anthelmintic.

Levamisole also affects immune responses. That separate property explains why it has appeared in specialist treatment protocols outside routine worm treatment, but it also helps explain the need for caution. In some people, levamisole can reduce white blood cell levels. The risk is especially relevant with repeated or prolonged dosing, when a prescriber may require complete blood-count testing. A single-dose regimen should not be extended or repeated without specific instructions.

Using the 150 mg Oral Tablet Safely

For established adult anthelmintic use, available product information identifies levamisole 150 mg as a single oral dose. Follow the prescription and the directions supplied with the exact product rather than assuming that every infection uses the same schedule. The tablet is swallowed by mouth with water. If the product label or prescriber gives instructions about food or timing, those directions take priority.

Do not take extra tablets because symptoms persist, and do not schedule a repeat dose independently. Some infections require reassessment, a different medicine, treatment of close contacts, or follow-up testing rather than more levamisole. If a clinician prescribes repeated dosing, ask when blood-count testing is needed and record both the dose and follow-up dates.

Avoid alcohol during treatment and ask a pharmacist or prescriber how long to avoid it before and after the dose. If dizziness, lethargy, or another neurological effect occurs, do not drive or operate machinery until the effect has passed and it is safe to do so.

Package Choices in Our Catalogue

We list Dicaris 150 mg tablets in quantities of 16, 32, 48, 60, 76, and 92 tablets. The available quantities do not indicate how many tablets a person should take. For common adult anthelmintic use, one 150 mg tablet may represent one prescribed dose, so even the smallest listed quantity can contain substantially more than one treatment dose.

Select a quantity only after the intended schedule and number of patients have been established by a prescriber. Do not assume that a larger package is appropriate for household treatment, future infections, or an unconfirmed long-term regimen. Medicine prescribed for one person should not be shared, and repeated specialist use requires its own monitoring plan.

What Results and Follow-Up Should You Expect?

Levamisole begins acting on susceptible parasites after it is taken, but treatment success cannot be confirmed simply by expecting visible worms or immediate symptom relief. Symptoms attributed to a worm infection can have other causes, and some people have few symptoms even when an infection is present. The expected response and need for follow-up depend on the organism, the original diagnosis, and the clinical setting.

A prescriber may recommend a stool test or another assessment after treatment in selected cases. Seek professional advice if symptoms continue, worsen, or return instead of repeating Dicaris without direction. Uses based on levamisole's effects on immune responses have different goals and timelines from anthelmintic treatment and require specialist supervision.

Contact a health care professional promptly if fever, sore throat, mouth ulcers, unusual fatigue, unexplained bruising, or other signs of infection develop after levamisole. These symptoms can have many causes, but they may also indicate a significant change in white blood cell levels and should not be ignored.

Blood Counts, Pregnancy, and Other Safety Priorities

The most important levamisole precaution is its potential to cause leukopenia or agranulocytosis, meaning a low or dangerously low white blood cell count. This can reduce the body's ability to fight infection. The concern is particularly important for anyone with a previous blood dyscrasia and for treatment involving repeated doses. When monitoring is prescribed, complete the blood tests on schedule rather than relying on symptoms alone.

Use during pregnancy should generally be avoided, especially in the first trimester, unless a clinician decides that it is clearly necessary. Breastfeeding also requires a specific professional decision because transfer into human milk has not been established and blood-related toxicity in an infant is a concern. The 150 mg tablet is not an appropriate way to estimate a child's dose; children require weight-based assessment and, when levamisole is chosen, an appropriate lower strength or dosing plan.

Dizziness, lethargy, headache, nausea, abdominal discomfort, or other adverse effects may occur. Severe allergic symptoms, marked weakness, neurological changes, fever, or signs of infection warrant prompt medical attention. Suspected adverse reactions to a health product can be reported to Health Canada through MedEffect Canada.

What Can Interact With Dicaris?

Alcohol is the clearest practical interaction. Combining alcohol with levamisole can cause a disulfiram-like reaction, an acutely unpleasant response that may include flushing, nausea, vomiting, headache, and a fast heartbeat. Avoid alcohol according to the instructions from the prescriber or pharmacist rather than trying to manage the reaction after it begins.

Because levamisole can affect blood cell counts, a clinician should review other medicines that can suppress bone marrow or lower white blood cells. This does not mean every medicine with a blood-related warning is prohibited, but the combination may change whether levamisole is suitable or whether monitoring is needed.

Provide a complete list of prescription medicines, non-prescription products, vitamins, and supplements before treatment. Also mention previous reactions to levamisole, blood-count abnormalities, liver disease, neurological symptoms, and alcohol use. Do not stop an essential prescribed medicine solely because of a general interaction warning; ask the prescriber or pharmacist how to manage the combination.

Which Antiparasitic Option May Be More Appropriate?

The best option depends primarily on the parasite and the patient's health, not on which medicine has the shortest schedule. Alternatives can differ in the organisms they treat, whether dosing is based on body weight, the need for repeat treatment, and their contraindications.

These medicines should not be ranked without knowing the organism involved. They also do not cover every type of parasite. Chloroquine, for example, has a distinct role against malaria parasites and is not an alternative for the intestinal worms treated with levamisole. Our Antiparasitics category can help readers identify products to discuss, but product selection should follow an appropriate diagnosis.

Canadian Prescription and Authorization Context

Levamisole and its salts are included on Health Canada's Prescription Drug List. An authorized human levamisole product therefore requires a prescription in Canada. This national classification is separate from our ordering process and should not be interpreted as optional because a product can be viewed in an online catalogue.

The available information does not identify a Canadian DIN or Canadian authorization holder for the exact Dicaris levamisole 150 mg tablets. That is not proof that no relevant record exists, but it means the exact package should be checked in Health Canada's Drug Product Database before supply or use. Confirm the product name, active ingredient, strength, oral tablet form, manufacturer, DIN, expiry information, and package labelling rather than relying on the ingredient name alone.

A prescriber can determine whether levamisole is clinically appropriate and issue a prescription when warranted. A pharmacist can help verify the medicine, review interactions, and explain whether the specific product can lawfully be supplied in Canada.

Planning an Order and Contacting Our Team

Once a prescriber has confirmed levamisole 150 mg and the required quantity, compare that treatment plan with the package sizes we list. Before completing an order, verify how the Canadian prescription and product-authorization requirements apply to the exact package. Do not select a larger quantity merely because it appears more convenient; the quantity should reflect a documented regimen.

Our support team is available 24/7 by email, online chat, and phone. We have supported customers since 2017, and pharmacist support is available for questions about the listed product, its storage, prescribed timing, and general medicine precautions. Our team can also clarify the current ordering information associated with the package under consideration.

No specific shipping method or delivery estimate is established in the supplied product information. Contact us to confirm the current options for your destination before ordering, and do not rely on an assumed arrival date when planning treatment. Keep the medicine in its original packaging after receipt and follow the labelled storage directions.

A Balanced Decision on Dicaris

Dicaris 150 mg offers a simple single-dose pattern for established adult treatment of certain susceptible worm infections, but convenience is only one part of the decision. The correct parasite diagnosis, blood-count history, pregnancy or breastfeeding, age and body weight, alcohol use, and other medicines all matter. Repeated or specialist use requires a separate dosing and monitoring plan.

For a customer in Canada, the prescription classification and the unresolved Canadian authorization details for the exact Dicaris product also need to be checked before supply or use. If a prescriber has selected levamisole, a pharmacist has verified the product, and the prescribed quantity matches one of the packages we list, the next step is to confirm the applicable ordering requirements with our support team. If any part of the diagnosis, product identity, or safety review remains uncertain, resolve it before taking the tablet.